Biotech

All Articles

AstraZeneca blog posts data on internal opponents to AbbVie, Pfizer ADCs

.AstraZeneca has discussed an early examine the functionality of its internal antibody-drug conjugat...

iTeos- GSK's TIGIT superstar shows purposeful remodeling

.After declaring a phase 3 launch based on beneficial midstage end results, iTeos and GSK are finall...

More joint FDA can easily increase uncommon condition R&ampD: report

.The FDA ought to be even more available as well as collaborative to release a rise in approvals of ...

Zenas, MBX, Bicara head to Nasdaq in warm time for biotech IPOs

.It is actually an extraordinarily occupied Friday for biotech IPOs, along with Zenas BioPharma, MBX...

Atea's COVID antiviral fails to stop hospital stays in period 3

.Atea Pharmaceuticals' antiviral has failed an additional COVID-19 trial, yet the biotech still keep...

Neurocrine's offer to spare schizophrenia prospect fails

.Neurocrine Biosciences' mental illness program pivot has neglected. The biotech was actually incapa...

Sanofi pays $110M upfront for late-stage radioligand treatment

.Sanofi has actually created a late access to the radioligand gathering, spending 100 thousand europ...

F 2G raises $100M for 2nd effort to receive brand-new antifungal to market

.After F2G's very first try to get a new course of antifungal to market was hindered by the FDA, the...

Moderna targets $1.1 B in R&ampD costs slices, drops 5 programs surrounded by success stress

.Moderna has pledged to reduce R&ampD investing by $1.1 billion through 2027. The choice to retract ...

Sanofi's $80M bank on Fulcrum dystrophy medication finishes in phase 3 lose big

.Simply 4 months after Sanofi wager $80 thousand in upfront cash on Pivot Rehabs' losmapimod, the pr...